UCLA researchers submit 11 projects to GSK for consideration before the July 19 deadline.

"GlaxoSmithKline plc (GSK) launched the Discovery Fast Track in May to allow academic researchers to form collaborations with the pharma to test disease-related hypotheses. Under the original terms of the precompetitive program, prospective participants were asked to submit brief, non-confidential disclosures to the pharma about their scientific ideas and plans for collaboration with GSK.

The program hit a snag when the technology transfer office of the University of California, Los Angeles barred researchers at that campus from participating. That policy soon was widened to cover the entire UC system.

Brendan Rauw, associate vice chancellor and executive director of entrepreneurship at the UCLA Office of Intellectual Property and Industry Sponsored Research, said there was concern about the potential for disclosure of confidential information and conflict with third-party rights to the researchers’ discoveries.

In June, GSK conducted discussions with Rauw and representatives of the UC Office of General Counsel and came up with a fix..."

[ Read Full Article ]

UCLA Licensee, Advanced Liquid Logic, Acquired by Illumina, Inc.
Acquisition is a key component in the development of next generation sequencing systems

Illumina, Inc. (NASDAQ:ILMN) today July 23, 2013 announced that it has acquired Advanced Liquid Logic (ALL), a leading provider of liquid handling solutions. ALL, now a wholly owned subsidiary of Illumina, has developed a proprietary “digital microfluidics” technology based on electrowetting that precisely manipulates small droplets within a sealed disposable cartridge to perform complex laboratory protocols. This proven technology will enable Illumina to deliver the simplest and most efficient sample-to-answer next-generation sequencing (NGS) workflow...

[ Read Full Press Release ]
[ Illumina, Inc. ]

TechTransfer 'Roundup:  UCLA Startup Funding and IP Licensing Developments
Highlighting selected startup funding and IP licensing announcements featured in previous issues of UCLA Invents.

• UCLA Licensee, Aragon Pharmaceuticals, Acquired by J&J for up to $1 Billion [ more]

• UCLA Biofuel Startup Raises $1.6 Million in Series "A" Round [ more]

• Quest PharmaTech Signs License Agreement with UCLA for anti - PSA IgE [ more]

• UCLA Licensee, Kite Pharma Inc., Completes $35 Million Series A Preferred Stock Financing [ more]

• BioTime Enters into License Agreement with UCLA to Develop Stroke Therapy [ more]

• ArmaGen Technologies Announces $17 Million Series A Financing [ more]

• C3 Jian Closes $30 Million Financing [more]
  

• UCLA Startup, Tribogenics, Raises $6.2 Million Series A Round Led by Peter Thiel's Founders Fund [more]

• UCLA Licensee, NeuroSigma, Announces Issued Patent on eTNS Technology for the Treatment of Neuropsychiatric Disorders [ more]

• UCLA Licensee, Kythera Biopharmaceuticals, Inc., Announces Closing of IPO  [more]

• UCLA Licensee, ImmunGene, Forms Joint Venture to Develop Antibody-Interferon Fusion Therapeutics to Treat Cancer [more]

• Islet Sciences Announces Exclusive License with UCLA to Commercialize Small Molecules for Islet Expansion [more]

UCLA INVENTS is published by UCLA's Office of Intellectual Property and Industry Sponsored Research (OIP-ISR). UCLA INVENTS highlights entrepreneurial and technology commercialization developments, and opportunities at UCLA.

PLEASE ATTENTION editorial comments, corrections, and topic suggestions to:  
Bob Nidever,   bnidever@research.ucla.edu

Editor
  Bob Nidever
Contributors 
  Erin Bowers
  Neil Bajpayee

To subscribe, please visit:   http://oip.ucla.edu/UCLAinvents   

UCLA INVENTS
UCLA Office of Intellectual Property and Industry Sponsored Research
11000 Kinross Ave., Suite 200; Los Angeles, CA 90095 | tel. 310-794-0558 |  http://oip.ucla.edu

Copyright 2013 UC Regents